Hoth Therapeutics Prepares Presentation on Clinical Programs

An update from Hoth Therapeutics ( (HOTH) ) is now available.

Hoth Therapeutics announced the preparation of presentation materials intended for use in presentations about the company’s operations and performance starting June 9, 2025. The materials highlight the company’s clinical programs, including the development of HT-001 for treating EGFR inhibitor-induced skin toxicities and HT-KIT for systemic mastocytosis. These developments are part of Hoth’s strategy to address unmet medical needs and expand its market presence, with significant milestones expected in the coming years.

The most recent analyst rating on (HOTH) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Hoth Therapeutics stock, see the HOTH Stock Forecast page.

More about Hoth Therapeutics

Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation therapeutics to meet unmet patient needs. The company is involved in early-stage pharmaceutical research and development, working on promising drugs for pre-clinical and clinical testing in areas such as oncology, neurology, dermatology, and inflammatory diseases.

Average Trading Volume: 1,059,952

Technical Sentiment Signal: Buy

Current Market Cap: $17.17M

Learn more about HOTH stock on TipRanks’ Stock Analysis page.